Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of September 2025, specifically dated September 15, 2025. The report serves to disseminate a press release regarding a significant regulatory milestone for the Company's next-generation XSense Cryoablation System.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative performance data.
Material Changes
The primary material change reported is the receipt of regulatory approval in Israel for the Company's next-generation XSense Cryoablation System. This approval covers indications for breast cancer and other potential uses, marking a strategic advancement in the Company's product portfolio.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" section from the attached press release (Exhibit 99.1). The document does not provide specific numerical guidance or detailed risk factors within the text of the Form 6-K itself, deferring to the incorporated press release for such commentary.
Investor Verification Checklist
- Verify the specific scope of the Israeli regulatory approval for the XSense Cryoablation System beyond breast cancer.
- Review the full text of the press release (Exhibit 99.1) for detailed forward-looking statements and associated risks.
- Confirm the timeline for commercial launch in Israel following this approval.
- Assess the impact of this approval on the Company's broader global regulatory strategy.